1. Home
  2. ANGO vs MRVI Comparison

ANGO vs MRVI Comparison

Compare ANGO & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AngioDynamics Inc.

ANGO

AngioDynamics Inc.

HOLD

Current Price

$10.41

Market Cap

439.8M

Sector

Health Care

ML Signal

HOLD

Logo Maravai LifeSciences Holdings Inc.

MRVI

Maravai LifeSciences Holdings Inc.

HOLD

Current Price

$3.00

Market Cap

472.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGO
MRVI
Founded
1988
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
439.8M
472.8M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
ANGO
MRVI
Price
$10.41
$3.00
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$19.33
$4.00
AVG Volume (30 Days)
234.4K
1.4M
Earning Date
04-02-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
81.92
14.29
EPS
N/A
N/A
Revenue
$291,010,000.00
$185,743,000.00
Revenue This Year
$9.11
$12.44
Revenue Next Year
$4.94
$7.90
P/E Ratio
N/A
N/A
Revenue Growth
10.17
N/A
52 Week Low
$8.36
$1.67
52 Week High
$13.99
$4.11

Technical Indicators

Market Signals
Indicator
ANGO
MRVI
Relative Strength Index (RSI) 38.54 36.71
Support Level $9.73 $2.88
Resistance Level $11.06 $3.99
Average True Range (ATR) 0.34 0.20
MACD -0.06 -0.06
Stochastic Oscillator 4.47 3.12

Price Performance

Historical Comparison
ANGO
MRVI

About ANGO AngioDynamics Inc.

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Share on Social Networks: